



Vaccines and Global Health: The Week in Review
13 November 2021 :: Issue 632
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents

- :: [Milestones - Perspectives](#)
- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

Milestones - Perspectives

:::::

WHASS2: Special session of the World Health Assembly referred to in decision WHA74(16)

29 November – 1 December 2021

Geneva, Switzerland | Virtual event

Draft provisional agenda: [SSA2/1 \(draft\)](#)

The World Health Assembly (WHA) will gather for a special session 29 November to 1 December to consider developing a WHO convention, agreement, or other international instrument on pandemic preparedness and response.

The WHA normally meets each May. This special session (the second in the history of the WHO) was called for in a decision adopted by the Member States at the Seventy-fourth World Health Assembly: [Decision WHA74\(16\)](#).

During the session, the Member States will consider the following single substantive agenda item: *Consideration of the benefits of developing a WHO convention, agreement or other international instrument on pandemic preparedness and response with a view towards the establishment of an intergovernmental process to draft and negotiate such a convention, agreement or other international instrument on pandemic preparedness and response, taking into account the report of the Working Group on Strengthening WHO Preparedness and Response to Health Emergencies.*

The Working Group on Strengthening WHO Preparedness and Response to Health Emergencies, established after the WHA74, has met on four occasions and considered findings from several bodies in preparing its report. The sessions will be public and webcast on this page and other WHO channels.

ZERO DRAFT Report of the Member States Working Group on Strengthening WHO Preparedness for and Response to Health Emergencies to the special session of the World Health Assembly

FOURTH MEETING OF THE WORKING GROUP ON STRENGTHENING WHO PREPAREDNESS AND RESPONSE TO HEALTH EMERGENCIES A/WGPR/4/3

Provisional agenda item 2

28 October 2021 :: 15 pages

:::::

:::::

Measles

Global progress against measles threatened amidst COVID-19 pandemic

The largest increase in unvaccinated children in 20 years and critical gaps in disease surveillance increase risk of measles outbreaks, putting lives at risk

New York, 10 November 2021: While reported measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to [a new report](#) from the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention (CDC). **During 2020, more than 22 million infants missed their first**

dose of measles vaccine – 3 million more than in 2019, marking the largest increase in two decades and creating dangerous conditions for outbreaks to occur.

Compared with the previous year, reported measles cases decreased by more than 80 percent in 2020. However, measles surveillance also deteriorated with the lowest number of specimens sent for laboratory testing in over a decade. Weak measles monitoring, testing and reporting for measles jeopardize countries' ability to prevent outbreaks of this highly infectious disease. **Major measles outbreaks occurred in 26 countries and accounted for 84 percent of all reported cases in 2020.**

"Large numbers of unvaccinated children, outbreaks of measles, and disease detection and diagnostics diverted to support COVID-19 responses are factors that increase the likelihood of measles-related deaths and serious complications in children," said Kevin Cain, MD, CDC's Global Immunization Director. "We must act now to strengthen disease surveillance systems and close immunity gaps, before travel and trade return to pre-pandemic levels, to prevent deadly measles outbreaks and mitigate the risk of other vaccine-preventable diseases."

Lower reported measles cases in 2020 must not mask the growing risk of measles to children worldwide

The ability of countries to ensure children receive both recommended doses of measles vaccine is a key indicator of global progress toward measles elimination and capacity to prevent the spread of the virus. **First-dose coverage fell in 2020, and only 70 percent of children received their second dose measles vaccine, well below the 95 percent coverage needed to protect communities from the spread of the measles virus.**

Adding to the worsening of immunity gaps worldwide, **24 measles vaccination campaigns in 23 countries, originally planned for 2020, were postponed because of the COVID-19 pandemic** – leaving more than 93 million people at risk for the disease. These supplemental campaigns are needed where people have missed out on measles-containing vaccines through routine immunization programs.

"While reported measles cases dropped in 2020, evidence suggests we are likely seeing the calm before the storm as the risk of outbreaks continues to grow around the world," said Dr Kate O'Brien, Director of WHO's Department of Immunization, Vaccines and Biologicals. "It's critical that countries vaccinate as quickly as possible against COVID-19, but this requires new resources so that it does not come at the cost of essential immunization programs. **Routine immunization must be protected and strengthened; otherwise, we risk trading one deadly disease for another."...**

:::::

:::::

Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, and UNICEF Announce \$150 Million Guarantee to Support Access to Vaccines and Health Supplies in Low- and Middle-Income Countries

New four-year commitment will help UNICEF procure COVID-19 tests, treatments, and vaccines; mitigate the pandemic's disruption of routine immunization; and support the procurement of other essential health supplies

SEATTLE – STOCKHOLM – COPENHAGEN (November 12, 2021) - The Bill & Melinda Gates Foundation, the Swedish International Development Cooperation Agency (Sida), and UNICEF today announced a **\$150 million financial guarantee to help UNICEF procure vaccines and other health-related supplies for low- and middle-income countries (LMICs)**.

This financing, effective through 2025, will help sustain national immunization programs, including COVID-19 vaccination campaigns, and enable the timely procurement of essential health supplies while domestic financing is mobilized. Many low- and middle-income countries rely on UNICEF's procurement services to secure access to a wide array of affordable essential health supplies as part of their emergency response and to meet routine needs. With the COVID-19 pandemic putting decades of work to improve child survival in jeopardy, this new financing will help improve the sustainable and reliable availability of essential and often lifesaving health supplies, such as diagnostics, syringes, and oxygen concentrators.

"The world cannot have a system in which supplies that are critical to improving the health of all people are auctioned to the highest bidder, forcing poorer countries to go without," said Chris Elias, president of the Global Development Division at the Bill & Melinda Gates Foundation. "Access to diagnostics, treatments, vaccines and other essential health supplies is critical to ensuring that countries can protect their people against COVID-19 and other health threats. This financial commitment will ensure that UNICEF is well-equipped to continue procuring affordable, lifesaving tools for those most in need."

"We at Sida are thrilled that we can deploy innovative financing mechanisms together with the Bill & Melinda Gates Foundation to allow UNICEF to scale up their operations," said Cecilia Scharp, director of International Organisations and Policy Support at Sida. "Health systems in low- and middle-income countries are disproportionately affected by the COVID-19 pandemic, and access to health commodities is of vital importance to combat impacts of the pandemic."...

:::::
:::::

Editor's Note

A "COVID-19 Ministerial" was convened by the U.S. State Department on November 10 [selected announcements below]. Readers will note that the aspirations outlined in the announcement of this meeting [...we will assess...we will discuss...we will discuss...we will also assess...] were well aligned with the results reported.

Press Statement

Announcement of the COVID-19 Ministerial

Antony J. Blinken, Secretary of State

November 5, 2021

[Excerpt]

...Foreign Ministers must play a central role to bring this pandemic to an end and prepare for the future. Together with my counterparts and leaders from regional and international organizations, **we will assess** the current state of the global response to COVID-19, the virus's impact, and the threat of future pandemics. **We will discuss** efforts to accelerate toward vaccine equity and impact. **We will discuss** the need for sustainable financing for global health security. **We will also assess** the role of

enhanced regional collaboration and coordinated political leadership in current and future preparedness and response...

10 November 2021 *Speech*

WHO Director-General's remarks at the COVID-19 Foreign Ministerial hosted by the United States of America

[Excerpt]

First, how do we end this pandemic? And second, how do we make the world safer? Let me start with the first question.

As you know, WHO's targets are to vaccinate 40% of the population of all countries by the end of this year, and 70% by mid-2022. Nearly 80 countries, half of them in Africa, will not reach our 40% vaccination target, without your help. To reach that target, we need an additional 550 million doses.

We ask you to establish immediately a high-level working group to identify and deliver those doses, and to give COVAX, AVAT and low-income countries the visibility they need so they can plan accordingly.

We ask high-coverage countries to give your place in the vaccine delivery queue to COVAX and AVAT, as the US has just done with a delivery of Moderna vaccines;

We ask those countries that have promised to donate vaccines to make good on those promises, as soon as possible.

We ask you to support local production of vaccines.

And we ask you to fully fund the ACT Accelerator, which needs 23.4 billion U.S. dollars over the next 12 months to get vaccines, tests, treatments and PPE to where they are needed most...

Press Statement

Innovative Next Steps in the Global COVID-19 Response

Antony J. Blinken November 10, 2021

[Excerpt]

...Today, I convened a COVID-19 Ministerial to discuss with foreign ministers representing every region of the world and representatives of international and regional organizations the status of our collective COVID-19 response and important steps forward. These include three new efforts.

First, to ensure that vaccine doses reach people in need, Global COVID Corps, a coalition of leading private sector companies, will provide pro bono expertise, tools, and capabilities to support logistics and vaccination efforts in low- and middle-income countries. This effort, which includes some of the largest U.S.-based and non-U.S based multinational corporations, will work with and support countries in key areas including supply management, supply chain logistics, vaccine site network infrastructure, vaccine site optimization, and demand generation. Governments, international and regional organizations, civil society and the private sector must continue to work together to defeat this pandemic.

We also must rely on data-driven tools to measure our progress towards meeting the ambitious targets set forth in President Biden's recent Summit, hold ourselves accountable to the commitments we have made, and identify gaps in our global response. To advance these goals of transparency and accountability and track the response, I welcome the launch of the Global COVID-19 Access Tracker, powered by the Multilateral Leaders Task Force (MLT) and the ACT-Accelerator. This site, located at COVID19GlobalTracker.org, includes a public-facing dashboard that tracks progress against the key global targets. Data will continually be uploaded and updated to enable all of us to track progress at the global, regional, and national level.

Finally, we need to ensure that people everywhere can access vaccines, and that those who cannot be reached by government vaccination campaigns are included in our efforts to vaccinate the world. The United States has helped broker an agreement between Johnson & Johnson and COVAX to facilitate the first delivery of Johnson & Johnson COVID-19 vaccine doses to people living in conflict zones and other humanitarian settings. We are committed to helping people in these difficult circumstances to get protection against COVID-19 as soon as possible.

Ending this global pandemic requires global solutions, cooperation, and innovation. We need political will, resources, and cooperation to succeed. During the course of the Ministerial, we discussed our shared commitment to rapidly expand the provision of vaccines so that we can meet the WHO's targets. We also discussed how to foster regional collaboration to address systemic challenges that have been laid bare by the pandemic. The United States is committed to working with partners to build increased regional capacity. Finally, we addressed the need to expand global production of vaccines and other vital medical supplies, an expansion that the United States has invested in and will continue to support, as well as what is needed to strengthen, govern and sustain an effective global health security architecture. I look forward to future convenings with foreign ministers, and to working together to end this pandemic everywhere, and for everyone.

Press Statement

Chair's Statement by U.S. Secretary of State Antony Blinken following the COVID-19 Ministerial

Antony J. Blinken November 10, 2021

[Excerpt]

...Recognizing that foreign ministers must play a leading role in advancing these efforts and must therefore engage on a regular basis to share views, forge plans and unite behind the actions needed to ensure the security of all nations, Secretary of State Antony Blinken on November 10, 2021 convened a virtual COVID-19 Ministerial. The meeting focused on ending the pandemic and building better health security to prevent, prepare for, and respond to infectious disease and other biological threats. Ministers discussed the state of the global response to and impact from COVID-19; meeting global vaccine coverage, diagnostic, and therapeutic targets; vaccine sharing principles, transparency, solidarity, and equity; the need for sustained financing to build global health security capacity; the role of regional collaboration and architecture in health security; and the need for coordinated political leadership in multisector responses to prevent future pandemics. In addition to welcoming the work of the Access to COVID-19 Tools Accelerator (ACT-A), Ministers underscored the importance of coalescing around shared targets, upholding and increasing political and financial commitments, and turning those commitments into action. The Ministerial provided an opportunity to identify gaps and solutions that require political leadership and launched what will be a series of regular engagements by foreign ministers.

Accelerating Towards Vaccine Equity and Impact: Vaccine Principles and Expanding Global Vaccine Manufacturing

Participants reiterated calls to work together to end the COVID-19 pandemic as soon as possible, with every country, partner, and organization doing its part, aligning around shared goals and targets, and holding each other to account. Ministers broadly aligned around the World Health Organization (WHO) vaccination targets and expressed shared urgency to do more, to enhance accountability, and to monitor progress. Reflecting on the state of vaccine supply and readiness, participants noted the role foreign ministers can play in accelerating vaccine access globally. Some Ministers raised cooperation, including a positive view towards sharing relevant data and information, to make safe and efficacious vaccines available, and supporting scientific and technological cooperation among national, regional and global institutions for research, development and production of vaccines and consumables...

.....
.....

International organizations, vaccine manufacturers take stock of COVID-19 vaccine roll out, share views for 2022

9 November 2021

The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization held on 9 November the 2nd High-Level Consultations with the CEOs of leading COVID-19 vaccine manufacturing companies. At the meeting, all participants agreed on the urgency of delivering more vaccine doses to low-income countries, where less than 2.5% of the population has been fully vaccinated.

The objective of the meeting was to identify how to ensure more equitable distribution of vaccines and all those participating pledged to continue working together to gain greater clarity on donations, vaccine swaps and delivery schedules so that distribution of the life-saving vaccines can be more effectively targeted towards those countries most in need...

During the consultations, the heads of the four organizations and the CEOs also examined how best to tackle trade-related bottlenecks; how to improve the donation process; what additional steps are needed to reach the vaccination target of 40% of people in all countries by the end of the year; and how to improve transparency and data sharing with the IMF-WHO Vaccine Supply Forecast Dashboard and the Multilateral Leaders Task Force, requiring close collaboration between manufacturers, governments and COVAX on enhanced visibility of delivery schedules, especially for donated doses.

The outlook for 2022 was also discussed, focusing on diversification of manufacturing across regions, as well as strengthening collaboration to achieve the global target of vaccinating 70% of the populations of all countries by the middle of the year. The group acknowledged progress in diversifying manufacturing, with new partnerships in multiple developing country regions, and stressed the need to continue to strengthen such manufacturing collaboration.

The heads of the organizations encouraged all G20 governments to join the effort to meet the vaccination target of 40% by end-2021 by allowing manufacturers to prioritize COVAX and African Vaccine Acquisition Trust (AVAT) contracts; streamlining donations to COVAX and pledging more doses; exploring possibilities for effective vaccine swaps with COVAX and the AVAT; and eliminating export restrictions to vaccines and their inputs.



The COVAX Humanitarian Buffer: Frequently Asked Questions:

8 November 2021 :: 15 pages - 38 questions

This FAQ document has been prepared by the IASC Working Group on the Humanitarian Buffer. The Working Group was tasked by the IASC Emergency Directors Group to work with Gavi, the Vaccine Alliance, on the establishment and operationalization of the COVAX Humanitarian Buffer. These FAQs are intended for all IASC entities, humanitarian partners, and external stakeholders. The FAQs will be updated and re-circulated as required to ensure they reflect the most relevant and up-to-date information.

[Selected FAQs/excerpts]

GENERAL

1. What is the COVAX Humanitarian Buffer?

The Humanitarian Buffer is a mechanism established within the COVAX Facility to act as a measure of 'last resort' to ensure access to COVID-19 vaccines for high-risk and vulnerable populations in humanitarian settings. The Humanitarian Buffer is only to be used where there are unavoidable gaps in coverage in national vaccination plans and micro-plans, despite advocacy efforts.

National governments are responsible for ensuring access to COVID-19 vaccines for all people within their respective territory. The 'first resort' for all populations of concern, irrespective of legal status, is that they are included in national vaccination plans and reached during the implementation of those plans. Gavi, IASC partners, civil society and others will continue to advocate with national governments to ensure the inclusion of all populations regardless of their legal status in line with the WHO Strategic Advisory Group of Experts on Immunization (SAGE) 'Values Framework' and 'Roadmap For Prioritizing Uses Of COVID-19 Vaccines in The Context Of Limited Supply' and will advocate for the revision of national plans and micro-plans if required.

POPULATIONS OF CONCERN FOR THE HUMANITARIAN BUFFER

6. Which groups are considered as populations of concern for the Humanitarian Buffer?

Populations of concern in humanitarian settings may include refugees, asylum seekers, stateless persons, internally displaced persons, minorities, populations in conflict settings or those affected by humanitarian emergencies, and vulnerable migrants irrespective of their legal status.

7. What is the estimated size of the populations of concern?

The IASC estimates there are approximately 167 million people at risk of exclusion from COVID-19 vaccination, noting that these numbers are highly variable and subject to change due to unexpected shocks (such as conflicts, natural disasters etc.). The current number of refugees, IDPs and stateless populations is over 80 million. Even in the ideal scenario of all countries including all populations of concern in their national plans, it is estimated that 60-80 million people in non-government-controlled areas could remain beyond national authorities' reach.

These estimates are based on data from the 2021 Global Humanitarian Overview (GHO). However, the populations of concern for the Humanitarian Buffer will not be limited to populations in the 2021 GHO. The Humanitarian Buffer is designed to be flexible and agile to respond to dynamic situations and risks of exclusion and can be used to reach any population of concern in a humanitarian setting that is not

being vaccinated by national authorities, regardless of whether or not they are included in the 2021 GHO.

8. How will populations of concern be prioritized? Will the Humanitarian Buffer vaccinate everyone caught up in humanitarian crises?

The Humanitarian Buffer is neither designed nor intended to cover the entirety of populations of concern, nor to prioritize them over any other population. Prioritization decisions will be in line with WHO SAGE guidelines, and will ensure parity with coverage levels and the standard COVAX vaccine rollout in a specific country. The Humanitarian Buffer intends to provide enough doses for high-risk groups within a given population of concern to cover frontline healthcare workers, the medically vulnerable, and those who meet nationally set age criteria. Based on IASC estimates, 20-30% of the 167 million people at risk of exclusion from COVID-19 vaccination would account for approximately 33-50 million people. Assuming a two-dose regimen, this would mean that a rough, indicative planning assumption would be that 66-100 million doses would be required for the Humanitarian Buffer. This target may shift with the evolution of the pandemic and the availability of supply globally.

19. How will Humanitarian Buffer allocation decisions be made?

A decision group comprising experts from IASC entities has been established to take decisions on allocations to the buffer and will report to the IASC EDG. They will receive secretariat support from the Joint Allocation Taskforce (JAT) of the COVAX Facility...The decision group will decide by consensus, based on the information provided. If, in exceptional circumstances, the decision group cannot reach consensus, it may refer the request to the Emergency Directors' Group (EDG) for input before deciding. The final decision remains with the decision group. Applications will be received on a rolling basis.

20. Which agencies are part of the IASC decision group?

The decision group will comprise of up to 10 IASC agencies: WHO, UNICEF, OCHA, IOM, UNHCR, ICRC, IFRC, MSF and a representative from the IASC's NGO consortia. Gavi will be an observer. WHO will chair the decision group. If a member of the decision group represents an organization which is applying to the buffer, that member will recuse themselves from consideration of the request in question.

30. Will there be a standard unit cost per dose for humanitarian buffer allocations?

Yes. The unit cost per dose of delivery will be set at between \$3.00 per dose. Certain contexts may have higher operational/ delivery costs, in which case additional funding will need to be mobilized. In some cases, UNICEF will be able to cover the additional costs of delivery. In other cases, other sources of financing will be required.

38. How will monitoring and evaluation and learning be undertaken for Humanitarian Buffer doses?

Countries, territories, and humanitarian agencies that receive doses through the Humanitarian Buffer will be responsible for reporting on their use. When applying for Humanitarian Buffer doses, applicants will be required to provide information on specific metrics within a specified timeframe following the implementation. UNCTs/HCs/RCs, and Health Clusters/Sectors will also support monitoring at country-level. With secretariat support from the JAT, the decision group will ensure that lessons learned are incorporated into its decision making.

:::::

:::::

:::::

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 12 Nov 2021

Confirmed cases :: 251 788 329 [248 467 363 week ago]

Confirmed deaths :: 5 077 907 [5 027 183 week ago]

Vaccine doses administered: 7 160 396 495 [7 027 377 238 week ago]

:::::

Weekly epidemiological update on COVID-19 - 2 November 2021


WHO

Overview

During the week 1 to 7 November 2021, a slight upward trend (1% increase) in new weekly cases was observed, with over 3.1 million new cases reported. Over 48 000 new deaths were reported, a 4% decrease from the previous week. The WHO European Region reported increases in case and death incidence, while other regions reported declines or stable trends. As of 7 November, over 249 million confirmed cases and over 5 million deaths have been reported.

In this edition, we provide an update on SARS-CoV-2 variants, including the current geographic distribution of Variants Concern (VOCs).

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 7 November 2021**



**See Annex 2: Data, table, and figure notes

:::::
:::::

WHO Director General Speeches [selected]
<https://www.who.int/director-general/speeches>

Selected

12 November 2021 *Speech*

WHO Director-General's opening remarks at the media briefing on COVID-19 - 12 November 2021

- **Almost 2 million cases of COVID-19 were reported in Europe last week, the most in a single week in that region since the pandemic started.**
- **Every day, there are six times more boosters administered globally than primary doses in low-income countries.** To reach WHO's target of vaccinating 40% of the population of every country by the end of this year, we need an additional 550 million doses – about 10 days' production. Vaccines alone will not end the pandemic, but we cannot end the pandemic unless we solve the global vaccine crisis.
- COVID-19 is not the only vaccine crisis we face. A new report by WHO and the US Centers for Disease Control and Prevention shows that more than 22 million infants missed their first dose of measles vaccine last year – 3 million more than in 2019, marking the largest increase in two decades.
- This Sunday is World Diabetes Day, and this year we are celebrating the 100th anniversary of insulin. One in every two people who need insulin for type 2 diabetes does not get it. A new WHO report finds that high prices, low availability of human insulin, a market dominated by 3 companies, and weak health systems are the main barriers to universal access.

:::::
:::::

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 11 November 2021

For 24 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title link above]

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.  BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized:	31/12/2020
							Additional sites: - Baxter Oncology GmbH Germany (DP) - Novartis Switzerland - Milbe (Dermapharm) Germany (DP) - Delpharm, Saint-Remy FRANCE (DP) - Shelf life extension: 09 months at -70 to -90°C - Sanofi-Aventis Deutschland GmbH Germany	30/06/2021 08/07/2021 16/07/2021 17/09/2021 20/09/2021 06/10/2021
		USFDA					Diluent suppliers: - Pfizer Perth, Australia/Fresenius Kabi, USA	18/06/2021
							Finalized: - Pharmacia & Upjohn, Kalamazoo (DP)/PGS - McPherson (DP) - Exelead, Inc. Indianapolis USA	16/07/2021 16/07/2021 30/09/2021
2.	AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
3.	AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional sites: - SK-Catalent - WuXi (DS) - Chemo Spain - Amlyn Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021
4.	AZD1222 Vaxzevria	Japan MHLW/PMDA		✓	✓	✓	Finalized: Additional sites: - Nipro Pharma Corporation Ise, Japan	15 Feb 2021
5.	AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional site: - Siam Bioscience Co., Ltd Thailand	09 July 2021 11 October 2021
6.								11 October 2021
7.	 Serum Institute of India Pvt. Ltd. Cyrus Poonawalla Group	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Finalized: DS and DP Manjari Bk Pune	15 Feb 2021 12 Nov 2021
8.	 Janssen-Cilag International NV	Ad26.COV.2.5	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	Core data finalized (US +NL sites)	12 March 2021
							Additional sites: - Merck, Durham, UK (DS) - - - Future submission - Merck, West Point/PA (DP)	-25 June 2021 -02 July 2021 - As submitted - 05 November 2021

WHO PREDQUALIFICATION



Manufacturer / WHO EUL holder	Name of Vaccine		Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
9.  Moderna Biotech	mRNA-1273		mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021
							Finalized: ModernaTx, Norwood (DS) - Catalent Indiana, LLC (DP) - Lemo Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	06 August 2021
10.  Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), inactivated (InCoV)	NMPA		✓	✓	✓	Finalized: 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC after ongoing inspection
11.  Sinovac Life Sciences Co., Ltd. / Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), inactivated/Coronavac™	NMPA	Inactivated, produced in Vero cells	✓	✓		Finalized: 2 dose presentation	01 June 2021 30 September 2021
12. 	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection-	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
13.  Bharat Biotech, India	SARS-CoV-2 Vaccine, inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	✓	Finalized	03 November 2021
14.  Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓		Rolling data started 23 July 2021	Ongoing
15.  CanSinoBio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓		Rolling data started 09 August 2021	Ongoing; inspection ongoing
16. 	NVX-CoV2373/Covax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓		Rolling data started 19 August 2021	Ongoing
17.  SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓			Rolling data started 30 July 2021	Ongoing
18.  Serum Institute of India Pvt. Ltd. / Cyrus Poonawalla Group	NVX-CoV2373/Covax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓			Rolling data started 21 September 2021	Ongoing
19. Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓		Rolling data started 20 September	Screened and communicated gaps. Data awaited
20.  CUREVAC	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Application withdrawn by manufacturer			
21. Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓	Presubmission planned			

Vaccines								Guidance Document 11 November 2021	
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02 Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission				

1. Beijing Institute of Biological Products Co Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech

- [Website not responding at inquiry]

Press Releases

BioCubaFarma – Cuba

Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

CanSinoBIO

News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China

News [Website not responding at inquiry]

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases

Nov 10, 2021 United States

[Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer](#)

:: COVAX Humanitarian Buffer ensures the world's most vulnerable people have access to COVID-19 vaccines

:: Approximately 167 million displaced people worldwide are at risk of exclusion from COVID-19 vaccination[1]

NEW BRUNSWICK, NJ (November 10, 2021) – Johnson & Johnson (NYSE: JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable

access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world's most vulnerable people. The first deliveries to the COVAX Humanitarian Buffer are anticipated to begin in the coming days...

Moderna

Press Releases

November 9, 2021

[Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years](#)

Submission based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11

Novavax

Press Releases

[Novavax Statement on UK and Mexico Phase 3 Clinical Trial Participants Considered Fully Vaccinated in the US](#) Nov 10, 2021

The US Centers for Disease Control and Prevention (CDC) provided updated guidance (Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States) stating that Novavax clinical trial participants from sites outside the US are considered fully vaccinated if they received the same product that was administered and independently evaluated in the US clinical trials. This means that participants in the UK and Mexico Phase 3 clinical trials are considered fully vaccinated if they received the full series of active Novavax COVID-19 vaccine...

Pfizer

Recent Press Releases

11.11.2021

[Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana](#)

Zipline successfully completes world's first long-range drone delivery of vaccines requiring ultra-cold-chain

...The collaboration of the companies, which worked together earlier this year to develop and test an end-to-end vaccine delivery solution, will allow for the distribution of approximately 50,000 doses of the Pfizer-BioNTech COVID-19 Vaccine in Ghana, pioneering a new model for vaccine distribution...

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases

[SINOVAC COVID-19 Vaccine Authorized for Commercial Sale in Myanmar](#)

2021/11/08

Vector State Research Centre of Virology and Biotechnology

[Home](#) - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

::::::

GSK

[Press releases for media](#)

12 November 2021 [Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19](#)

Merck

[News releases](#)

[Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval](#)

11/10/2021

[Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults](#)

11/9/2021

Novartis

[News](#) - No new digest announcements identified

SK Biosciences

[Press releases](#)

[SK bioscience Announces Positive Data from Phase I/II Clinical Trial of COVID-19 Vaccine Candidate](#)

2021. 11. 05

Valneva

[Press Releases](#)

[Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001](#)

November 10, 2021

::::::

::::::

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 13 Nov 2021](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



Deal date	Country/territory/group	Deal type	Vaccine developer
10/26/2021	African Union	Multilateral	Moderna
10/28/2021	Brazil	Bilateral	AstraZeneca
10/28/2021	United States of America	Bilateral	Pfizer BioNTech
10/29/2021	India	Bilateral	Bharat Biotech
10/29/2021	India	Bilateral	Serum Institute of India
10/29/2021	India	Bilateral	Zydus Cadila

▪▪▪▪
▪▪▪▪

IMF-WHO Vaccine Supply Forecast Dashboard

Updated on 8 November 2021

Many countries are not on track to meet the 40% vaccine coverage target. To make progress towards this target, we must identify: (1) Where and in which countries are the gaps?, and (2) How can gaps be addressed?

The IMF-WHO COVID-19 Vaccine Supply Forecast Dashboard estimates expected month vaccine supply until the end of 2021 by country, product and channel. The tracker builds on the work of the IMF Staff Discussion Note – A Proposal to End the COVID-19 Pandemic (Agarwal and Gopinath, 2021).

3. Gap to 40% and Excess Doses by Country Group

End-Dec End-Nov End-Oct End-Sep

Baseline Scenario Low Supply Scenario High Supply Scenario

Gap to 40% expected coverage				
	World	AMC91	High Income Countries	UMIC (excl. China)
Number of countries not on track to reach 40% coverage	73	60	0	13
Number of doses (mn.) needed for all countries to reach 40% coverage	563	539	0	24

Excess doses above 100% expected coverage

Number of countries on track to reach above 100% coverage	48	3	39	5
Number of excess doses (mn.) expected above 100% coverage	637	0	474	77

Other

Total number of countries	196	91	60	43
Total population (mn.)	7,868	2,587	1,236	1,208
Total number of doses supplied (mn.)	11,025	1,779	2,910	1,758
Total effective coverage (%)	70	34	118	73

Source: IMF & WHO Staff calculations. Effective vaccine supply = doses/2/population. J&J and CanSino volumes have been doubled for comparability with the other two dose candidates in the portfolio.



Duke – Launch and Scale Speedometer The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)


[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries ▾



Data updated on November 12th 2021.

Duke | GLOBAL HEALTH
Innovation Center




Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 13 Nov 2021]: <https://data.undp.org/vaccine-equity/>
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)

High income countries: 1 in 2
people, or



64.99%

have been vaccinated with at least
one dose as of Nov 12, 2021.

[WHO](#)

Low income countries: 1 in 15
people, or




6.48%

have been vaccinated with at least
one dose as of Nov 12, 2021.

[WHO](#)

High income countries have to
increase their health care spending
by




0.8%

on average to cover cost of
vaccinating 70% of the population.

[UNDP Survey](#), [WHO](#), [UNICEF](#)

Low income countries have to
increase their health care spending
by



56.6%

on average to cover cost of
vaccinating 70% of the population.

[UNDP Survey](#), [WHO](#), [UNICEF](#)

:::::
:::::

COVID Vaccines – OCHA::: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

13 Nov 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 252M total confirmed cases; 5.1M total confirmed deaths

Global vaccines administered: 7.41B

Number of Countries: 30 [29 week ago]

COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]

COVAX Delivered (Number of Doses): 140M [130M week ago]

Other Delivered (Number of Doses): 250M [230M week ago]

Total Delivered (Number of Doses): 390M [360M week ago]

Total Administered (Number of Doses): 310M [300M week ago]

::::::

::::::


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **13 Nov 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



Doses ?

● Required Doses (end 2021)

6.2B doses

(40% of total population)

● Required Doses (mid 2022)

10.9B doses

(70% of total population)

● Secured Vaccines / Expected Vaccine Supply


18B doses

● Delivered Doses

8.3B doses

● Doses Administered

7.3B doses



Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 13 Nov 2021]

:: **51.6%** of the world population has received at least one dose of a COVID-19 vaccine.


:: **7.45 billion doses** have been administered globally, and **31.1 million** are now administered each day.

:: Only **4.5%** of people in low-income countries have received at least one dose.

Share of the population fully vaccinated against COVID-19, Nov 12, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data – Last updated 13 November 2021, 11:20 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

► Dec 13, 2020


Nov 12, 2021

Share of the population fully vaccinated against COVID-19, Nov 12, 2021

Our World
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

[+ Add country](#)



Source: Official data collated by Our World in Data – Last updated 13 November 2021, 11:20 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

► Dec 13, 2020

Nov 12, 2021

::::::

::::::

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

CDC-ACIP

[ACIP Meetings](#)

:: Next Posted Meeting Date - February 23-24, 2022

::::::

FDA

[Press Announcements](#)

[November 12, 2021 - Coronavirus \(COVID-19\) Update: November 12, 2021](#)

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

No meetings on [calendar](#)

::::::

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Statement from President Joe Biden Announcing His Intention to Nominate Dr. Robert Califf for Commissioner of Food and Drugs](#)

November 12, 2021 • Statements and Releases

I first want to thank Dr. Janet Woodcock for her leadership over the last year. She has done an incredible job leading the agency during what has been a busy and challenging time, and both she and the FDA career staff have worked hard and followed the science to ensure the American public can trust the decisions being made by the FDA.

Dr. Robert Califf is one of the most experienced clinical trialists in the country, and has the experience and expertise to lead the Food and Drug Administration during a critical time in our nation's fight to put an end to the coronavirus pandemic. As the FDA considers many consequential decisions around vaccine approvals and more, it is mission critical that we have a steady, independent hand to guide the FDA. I am confident Dr. Califf will ensure that the FDA continues its science and data driven decision-making. Dr. Califf had strong bipartisan support in the Senate in 2016, and I urge the Senate to swiftly confirm Dr. Califf so he can continue the important work being done at this critical moment.

[Dr. Robert Califf, Nominee for Commissioner of Food and Drugs](#)

Dr. Califf is an internationally recognized expert in clinical trial research, health disparities, healthcare quality, and cardiovascular medicine. He brings nearly four decades of experience as a doctor, researcher, leader, and public servant, including previous service as FDA Commissioner from 2016-2017, for which he was confirmed by the Senate 89-4 with broad bi-partisan support. Currently, Califf is a professor of medicine at the Duke University School of Medicine, where he previously served as Vice Chancellor and founded the Duke Clinical Research Institute, and also works as Head of Clinical Policy at Verily Life Sciences, a life sciences research organization. Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

November 10, 2021 • Press Briefings

[FACT SHEET: Biden Administration Announces New Investments to Support COVID-19 Response and Recovery Efforts in the Hardest-Hit and High-Risk Communities and Populations as COVID-19 Health Equity Task Force Submits Final Report](#)

November 10, 2021 • Statements and Releases

[Memorandum for the Secretary of Homeland Security and the Administrator of the Federal Emergency Management Agency on Maximizing Assistance to Respond to COVID-19](#)

November 09, 2021 • Presidential Actions

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Press Releases

Virtual COVID-19 Ministerial

November 10, 2021

Press Statement

Innovative Next Steps in the Global COVID-19 Response

Antony J. Blinken November 10, 2021

Press Statement

Chair's Statement by U.S. Secretary of State Antony Blinken following the COVID-19 Ministerial

Antony J. Blinken November 10, 2021

[See Milestones/Perspectives above for detail]

::::::

::::::

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

News: COVID-19: EMA recommends authorisation of two monoclonal antibody medicines (updated)

CHMP, Last updated: 12/11/2021

News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021 (new)

CHMP, Last updated: 12/11/2021

News: EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11 (new)

CHMP, Last updated: 10/11/2021

::::::

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

Publication

Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA

Technical report - 11 Nov 2021

News

New update of the ECDC COVID-19 Vaccine Tracker

News story - 10 Nov 2021

::::::



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose in the total population in EU/EEA	Cumulative uptake of full vaccination in the total population in EU/EEA
69.6%	64.9%

Accessed 13 Nov 2021

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 11 November 2021

European Health Union: green light for two new COVID-19 therapeutics

Today, the European Medicines Agency (EMA) has given a positive opinion on two COVID-19 treatments - Ronapreve and Regkirona - identified by the Commission as promising therapeutics under the EU Strategy on COVID-19 Therapeutics.

Press release 10 November 2021

Coronavirus: Commission approves contract with Valneva to secure a new potential vaccine

Today, the European Commission approved the eighth contract with a pharmaceutical company with a view to purchasing its potential vaccine against COVID-19. The contract with Valneva provides for the possibility for all EU Member States to purchase almost 27 million doses in 2022. It also includes the possibility to adapt the vaccine to new variant strains, and for Member States to make a further order of up to 33 million additional vaccines in 2023...

::::::

::::::

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment



Africa CDC Vaccine Dashboard

Africa Vaccinated

Vaccine Administered (Total)	(57.09% of supply)
Partially Vaccinated	(9.20% of population)
Vaccination Completed	(6.06% of population)

Total of Supply Administered



Vaccines received from COVAX

50
Countries

Vaccines received bilaterally

49
Countries

Vaccines received from AVATT

34
Countries

Accesses 13 Nov 2021. Full scale, interactive dashboard available at:

<https://africacdc.org/covid-19-vaccination/>

:::::::
:::::::

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

No new digest content identified.

:::::::
:::::::

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
13 November 2021, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.40%)

136308 (1108↓)

Discharged (98.26%)

33826483 (12403↑)

Deaths (1.35%)

463245 (555↑)

COVID-19 Vaccination
as on : 13 November
2021, 08:00 IST
(GMT+5:30)

Total Vaccination : 1,11,40,48,134 (58,42,530↑)

Latest Updates

11.11.2021 [Guidelines for International Arrivals](#)

11.11.2021 [Algorithm for 'Guidelines for International Arrivals' \(dated 11th November 2021\)](#)

Government of India – Press Information Bureau

Latest Press Releases

COVID-19 Vaccination Update - Day 302

:: India's cumulative vaccination coverage crosses 111.95 crore

:: More than 52 lakh Vaccine doses administered today till 7 pm

Posted On: 13 NOV 2021

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

::::::

::::::

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

About 2.355b COVID-19 vaccine doses administered on Chinese mainland

2021-11-12

::::::

::::::

::::::

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 10 November 2021

:: Tajikistan has responded with full commitment and with the dedicated support of Global Polio Eradication Initiative partners to stop this outbreak," said Dr Victor Olsavszky, WHO Representative and Head of the WHO Country Office in Tajikistan. [Read more...](#)

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **Congo**: one cVDPV2 positive environmental sample
- **Côte d'Ivoire**: one cVDPV2 case
- **Gambia**: three cVDPV2 positive environmental samples
- **Niger**: three cVDPV2 cases
- **Nigeria**: 19 cVDPV2 positive environmental samples
- **Senegal**: one cVDPV2 positive environmental sample

:::::::
::::::

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Afghanistan crisis](#) [Last apparent update: 5 Aug 2021]

[Crisis in Northern Ethiopia](#) [Last apparent update: 18 Oct 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) [Last apparent update: 17 Aug 2021]

[Ebola outbreak, N'Zerekore, Guinea, 2021](#) [Last apparent update: 17 Aug 2021]

[Coronavirus disease \(COVID-19\) pandemic](#) [See COVID above]

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) [Last apparent update: 24 July 2018]

[Yemen crisis](#) [Last apparent update: 12 February 2021]

[Syria crisis](#) [Last apparent update: 18 June 2021]

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 1 Oct 2021]

[**Ebola outbreak, Democratic Republic of the Congo, 2017**](#) [Last apparent update: 17 Aug 2021]

[**Zika virus disease outbreak, 2015-2016**](#) [Last apparent update: 24 Jan 2020]

[**Ebola outbreak: West Africa, 2014-2016**](#) [Last apparent update: 17 Aug 2021]

[**Iraq crisis**](#) [Last apparent update: 9 Jan 2008]

[**South Sudan crisis**](#) [Last apparent update: 23 Sep 2020]

[**Avian influenza A \(H7N9\) virus outbreak**](#) [Last apparent update: 13 September 2021]

[**Middle East respiratory syndrome \(MERS-CoV\) outbreak**](#) [Last apparent update: 8 July 2019]

[**Influenza A \(H1N1\) virus, 2009-2010 pandemic**](#) [Last apparent update: 10 Aug 2010]

::::::

[**UN OCHA – Current Emergencies**](#)

Current Corporate Emergencies

Afghanistan

[**Afghanistan: Weekly Humanitarian Update \(1 – 7 November 2021\)**](#)

Northern Ethiopia

[**Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 11 Nov 2021**](#)

HIGHLIGHTS

- An estimated 2.7 million children in northern Ethiopia are affected by destroyed or damaged schools or by IDPs sheltering in schools.
- It is estimated that 80 per cent of essential medication is no longer available in Tigray while most health facilities are not functional due to damage and lack of supplies.
- The cancer treatment program at Ayder referral Hospital in Tigray has closed, leaving some 500 patients without treatment.
- Nearly 7,000 children in Amhara reached with learning programs, school feeding, scholastic materials, and temporary learning spaces.
- Two revised response plans for Ethiopia released capturing new needs, including in northern Ethiopia, with funding gaps of \$US 1.3 billion.

::::::

::::::

WHO & Regional Offices [to 13 Nov 2021]

<https://www.who.int/>

Selected News, Statements

12 November 2021

Joint News Release

[**Joint Research Centre and World Health Organization join forces to use behavioural insights for public health**](#)

12 November 2021

News release

New WHO report maps barriers to insulin availability and suggests actions to promote universal access

11 November 2021

Departmental news

More countries committing to tackling antimicrobial resistance

10 November 2021

News release

Global progress against measles threatened amidst COVID-19 pandemic

[See Milestones/Perspectives above for detail]

10 November 2021

News release

The Future is Unwritten - Healing Arts Symposium

10 November 2021

Statement

International organizations, vaccine manufacturers take stock of COVID-19 vaccine roll out, share views for 2022

[See Milestones/Perspectives above for detail]

10 November 2021

Departmental news

WHO, faith partners and national governments –supporting national responses to COVID-19

9 November 2021

News release

Countries commit to develop climate-smart health care at COP26 UN climate conference

::::::

Weekly Epidemiological Record, Vol. 96, No. 45, pp. 549–556 12 November 2021

:: Progress towards regional measles elimination – world-wide, 2000–2020

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: COVID-19 more deadly in Africans with diabetes 11 November 2021

Africa's sharp increase in diabetes is clashing with the COVID-19 pandemic and poor access to vaccines. Africa's death rates from COVID-19 infections are significantly higher in patients with

diabetes, according to a preliminary analysis which the World Health Organization (WHO) presented today in advance of the World Diabetes Day on 14 November...

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

- :: If not now, when? 100 years after the discovery of insulin, World Diabetes Day highlights the major gaps in diabetes care 12-11-2021
- :: 60% of migrants who spoke to WHO/Europe on the Belarus-Lithuania border need some form of medical attention 12-11-2021
- :: WHO/Europe highlights the health urgency for climate action at COP26 11-11-2021
- COP26: Policies and tools for health-centric climate action 11-11-2021
- :: Too much for one planet: WHO study proposes new tools to make our diets healthy and environmentally friendly 11-11-2021

WHO Eastern Mediterranean Region EMRO

- :: Somalia receives shipment of COVID-19 vaccines donated by the United States Government through COVAX Facility 8 November 2021
- :: Iraq launches nationwide vaccination campaign to scale up immunity against COVID-19 8 November 2021

WHO Western Pacific Region

No new digest content identified

:::::

New WHO Publications [Selected]

<https://www.who.int/publications/i>

Selected Titles

12 November 2021

[**Keeping the 100-year-old promise: making insulin access universal**](#)

12 November 2021

[**Global breastfeeding scorecard 2021: protecting breastfeeding through bold national actions during the...**](#)

11 November 2021

[**Maternal and perinatal death and surveillance and response**](#)

9 November 2021

[**Framework for strengthening health emergency preparedness in cities and urban settings**](#)
Overview

Cities and urban settings are crucial to preventing, preparing for, responding to, and recovering from health emergencies, and therefore enhancing the focus on urban settings is necessary for countries pursuing improved overall health security.

WHO has published the Framework for Strengthening Health Emergency Preparedness in Cities and Urban Settings in order to support policy-makers and decision-makers in the public health sector, as well as other relevant actors and stakeholders across sectors that are engaged in health emergency preparedness in cities and urban settings. In particular, it aims to: a) provide an overview of, and insight into, the key areas that national and subnational authorities may consider focusing on in strengthening health emergency preparedness at the urban level, and b) guide and support the development of policies and capacity building activities at both the national and sub-national level to strengthen health emergency preparedness in cities and urban settings, based on priority risks and existing gaps...

:::::
:::::

CDC/ACIP [U.S.] [to 13 Nov 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[CDC/NIOSH to Host Panel Discussion on Protecting Health Worker Mental Health: A Call to Action](#)

Friday, November 12, 2021

[Global Progress Against Measles Threatened Amidst COVID-19 Pandemic](#)

Wednesday, November 10, 2021

[ACIP Meetings](#)

:: Next Posted Meeting Date - February 23-24, 2022

[MMWR News Synopsis Friday, November 12, 2021](#)

Selected Content

:: [Progress Toward Regional Measles Elimination — Worldwide, 2000–2020](#)

:: [HIV Prevention Program Eligibility Among Adolescent Girls and Young Women — Namibia, 2019](#)

:: [Influenza Vaccinations During the COVID-19 Pandemic — 11 U.S. Jurisdictions, September–December 2020](#)

:: [The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021](#)

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

11/12/21

[Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 12 Nov 2021 06:00:00 EST](#)

11/10/21

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021

:::::
:::::

Africa CDC [to 13 Nov 2021]

<http://www.africacdc.org/>

News

Outbreak Brief 95: Coronavirus Disease 2019 (COVID-19) Pandemic

9 November 2021

... As of 9 a.m. East African Time (EAT) 9 November 2021, a total of 8,548,064 COVID-19 cases and 219,787 deaths (CFR: 2.6%) have been reported in 55 African Union (AU) Member States. This represents 3.4% of all cases and 4.4% of all deaths reported globally. Twenty-seven (49%) AU Member States are reporting CFRs higher than the global CFR. Since the beginning of the pandemic, 54 (98%) AU Member States have experienced at least a second wave, 46 (84%) have experienced a third wave and nine countries (Algeria, Benin, Burkina Faso, Egypt, Kenya, Mali, Mauritius, Somalia and Tunisia) have experienced a fourth wave of COVID-19 cases...

:::::
:::::

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 13 Nov 2021]

<http://en.nhc.gov.cn/>

News

Nov 13: Daily briefing on novel coronavirus cases in China

On Nov 12, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 75 new cases of confirmed infections.

About 2.355b COVID-19 vaccine doses administered on Chinese mainland

2021-11-12

New COVID-19 cases in Beijing linked to oil company conference

Updated: 2021-11-12 | China Daily

A new cluster of COVID-19 cases in Beijing has involved a wider range of areas and more people with its fast spread, adding difficulties to the capital's epidemic control and prevention, a senior official said on Thursday.

Beijing is facing a severe and complicated epidemic control and prevention situation that requires the departments involved to act with speed and precision to reduce transmission of the virus—that was the consensus at a meeting of the city's top epidemic control and prevention work group hosted by Beijing's Party Secretary Cai Qi on Thursday morning.

Unlike the last outbreak in the city, in which every case was linked to a tour group that traveled to the Inner Mongolia autonomous region, the new cases in Beijing are all related to a conference held in the city.

Beijing reported six locally transmitted cases and one asymptomatic case on Thursday and many of the patients are employees of PetroChina Co, which is headquartered in the capital, said Pang Xinghuo, deputy director of the Beijing Center for Disease Control and Prevention.

Those employees had been to a company conference in Beijing between Oct 28 and Wednesday. A participant in the conference was later confirmed in Jilin province to be infected with COVID-19...

National Medical Products Administration – PRC [to 13 Nov 2021]

<http://english.nmpa.gov.cn/>

News

[Website not responding at inquiry]

CCDC Weekly - [Weekly Reports: Current Volume \(3\)](#)

2021-11-12 / No. 46

[View PDF of this issue](#)

:: [Methods and Applications: Machine Learning Approach Effectively Predicts Binding Between SARS-CoV-2 Spike and ACE2 Across Mammalian Species — Worldwide, 2021](#)

:: [Methods and Applications: Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021](#)

:: [Review: Epidemiology Features and Effectiveness of Vaccination and Non-Pharmaceutical Interventions of Delta and Lambda SARS-CoV-2 Variants](#)

:: [Notes from the Field: Two Cases of COVID-19 with Persistently Positive SARS-CoV-2-Specific IgM During One-Year Follow-Up — Sichuan Province, China, February 2021](#)

:: [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, September, 2021](#)

:::::
:::::
:::::

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 13 Nov 2021]

<https://alleninstitute.org/news-press/>

News

Press Release

[Allen Institute announces 2021 Next Generation Leaders](#)

November 8, 2021

Six early-career neuroscientists will participate in unique advisory council for the Institute

BARDA – U.S. Department of HHS [to 13 Nov 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 13 Nov 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

[Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, and UNICEF Announce \\$150 Million Guarantee to Support Access to Vaccines and Health Supplies in Low- and Middle-Income Countries](#)

Press release

Nov 12, 2021

[See COVID above for detail]

Bill & Melinda Gates Medical Research Institute [to 13 Nov 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 13 Nov 2021]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 13 Nov 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Informed Consent: A Monthly Review – November 2021](#)** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 13 Nov 2021]

<http://cepi.net/>

Latest News

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [to 13 Nov 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 13 Nov 2021]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 13 Nov 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 13 Nov 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 13 Nov 2021]

<http://www.euvaccine.eu/>

Latest News

[PrIMAVeRa, a new ambitious project to demonstrate how vaccines can combat antimicrobial resistance](#)

The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking mobilises more than € 9 million to support PrIMAVeRa, a new public-private partnership dedicated to harnessing the power of big data and AI to steer the fight against antimicrobial resistance.

9 November 2021

Fondation Merieux [to 13 Nov 2021]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 13 Nov 2021]

<https://www.gavi.org/>

News releases

12 November 2021

[India completes national introduction of pneumococcal conjugate vaccine](#)

:: Over 90% of children born in India every year will have access to the vaccine thanks to the efforts of the Government of India, Gavi, the Vaccine Alliance and partners, who collaborated on the nationwide introduction of PCV into the country's routine immunisation programme.

:: India has received more than 60 million doses of the vaccine procured through the Gavi Pneumococcal Advance Market Commitment mechanism.

12 November 2021

Pakistan set to vaccinate more than 90 million children as part of global fight against measles and rubella

:: The campaign is one of the largest in history and will aim to reach over 95% coverage. Oral polio vaccine will also be integrated in the campaign to support polio eradication in Pakistan.

:: Dr Faisal Sultan, Special Assistant to the Prime Minister on Health: "Pakistan is proud to launch one of the largest measles rubella campaigns in the world, which will target millions of children."

:: The nationwide campaign is supported by Gavi, the Vaccine Alliance, UNICEF, WHO and partners.

GHIT Fund [to 13 Nov 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 13 Nov 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

United States to Host Next Global Fund Replenishment Conference

11 November 2021

The Global Fund to Fight AIDS, Tuberculosis and Malaria enthusiastically welcomes President Joe Biden's decision to host the Global Fund's Seventh Replenishment Conference in the United States in the second half of 2022.

News

Lifeline Support from UNDP and the Global Fund Keeps Afghanistan's Health Facilities Open

11 November 2021

Afghans in need of health care services can now benefit from the initiative of UNDP and the Global Fund to inject acutely needed funding and support into the deteriorating health care system, allowing it to continue to provide essential health care a...

News

Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness

10 November 2021

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria approved the new *Global Fund Strategy: Fighting Pandemics and Building a Healthier and More Equitable World*. The new Strategy places people and communities front and center of the f...

News

Global Fund Crosses US\$4 billion Mark in Funding to Support Countries in the Fight Against COVID-19

08 October 2021

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 13 Nov 2021]

<https://www.glopid-r.org/news/>

News

GloPID-R News & Events Round-Up

09/11/2021

Hilleman Laboratories [to 13 Nov 2021]

<http://www.hillemanlabs.org/>

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 13 Nov 2021]

<https://www.hhmi.org/news>

Press Room

Research Nov 9 2021

Codetta Program Deciphers Genetic Code in 250,000 Genomes

Codetta, a new computational method for predicting genetic codes, could reveal insights into how some organisms have modified a code once thought to be universal.

Human Vaccines Project [to 13 Nov 2021]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Nov 11, 2021

Tobias Kollmann: Unraveling the Complexities of Immunity to Improve Infant Health

Publication

Nov 09, 2021

Machine Learning-Based Single Cell and Integrative Analysis Reveals That Baseline mDC Predisposition Correlates With Hepatitis B Vaccine Antibody Response

IAVI [to 13 Nov 2021]

<https://www.iavi.org/newsroom>

Latest News

November 10, 2021

Enabling the next generation of science leaders

Strengthening research and science leadership capacity of African researchers

IAVI boat with clinic team in Uganda

IAVI, through its USAID-funded ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) program, is cultivating a core group of researchers and scientists in African institutions to participate in the global effort to identify, evaluate, and implement HIV vaccines and biomedical prevention products in the fight against HIV, and to contribute toward solving other pressing global health needs...

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 13 Nov 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

COP 26: Urgent action needed for low-income countries falling further behind in climate funding

At a high-level event on the sidelines of COP26 Thursday, governments and partners from development, civil society and humanitarian fields joined the African Development Bank and ICRC to call for greater recognition of the increased vulnerability fac

12-11-2021 | News release

ICRC leads discussion on the management of scarce water resources during protracted armed conflict

This high-level event will take place as part of the 13th session of the Arab Ministerial Water Council in Cairo on 17 November 2021, with the participation of ministers of water resources from the Arab States.

11-11-2021 | Report

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 13 Nov 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

12/11/2021

IFRC is extremely concerned about the worsening humanitarian situation in Palestine

11/11/2021

Communities affected by Hurricanes Eta and Iota are ...

09/11/2021

"COP26 has not gone far enough" says IFRC Secretary ...

Institut Pasteur [to 13 Nov 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 13 Nov 2021]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

12 Nov 2021

IOM, UNHCR Provide Emergency Aid to Asylum-Seekers and Migrants at the Belarus-Poland Border, Call to Ensure Wellbeing of People and Prevent Loss of Life

News

10 Nov 2021

IOM and EIB Join Forces to Promote Safety of Migrants and Resilience of Affected Communities

News

09 Nov 2021

COP26: Direct Linkages Between Climate Change, Health and Migration Must be Tackled Urgently – IOM, WHO, Lancet Migration

News

09 Nov 2021

IOM and UNHCR Call for Immediate De-escalation at the Belarus-Poland Border

ISC / International Science Council [to 13 Nov 2021]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Blog

World Science Day for Peace and Development: supporting at-risk, displaced and refugee scientists.

10.11.2021

A call to action from UNESCO-TWAS, IAP and ISC in the framework of the Science in Exile initiative to support at-risk, displaced and refugee scientists.

... In March 2021, UNESCO-TWAS, ISC and IAP launched the [Science in Exile initiative](#), the groundwork for which was laid in 2017. The initiative aims to create a network of like-minded organizations that work together to develop a platform, and roll out an advocacy campaign, so as to respond cohesively to the need of at-risk, displaced and refugee scientists.

Today, Science in Exile brings together almost a hundred displaced scientists and about 50 stakeholders worldwide, including international organizations, universities, research institutions and science academies, and organizations specialized in supporting at-risk, displaced and refugee scholars...

IVAC [to 13 Nov 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 13 Nov 2021]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 13 Nov 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/ Médecins Sans Frontières [to 13 Nov 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

Mali

Three questions on the challenges of treating cancer in Mali

Interview 11 Nov 2021

Haiti

Shortages of fuel, water threaten medical care in Haiti

Press Release 10 Nov 2021

Yemen

The rise of severe mental health conditions in Yemen

Interview 10 Nov 2021

Afghanistan

Malnutrition soars in Herat as healthcare reaches breaking point

Interview 10 Nov 2021

National Academy of Medicine - USA [to 13 Nov 2021]

<https://nam.edu/programs/>

Selected News/Programs/Events

NAM Releases Special Publication of Priorities on the Health Horizon

November 9, 2021

To inform the next steps in their organizational strategy, the Patient-Centered Outcomes Research Institute (PCORI), enlisted the National Academy of Medicine (NAM) to convene meetings of experts to identify emerging priorities for the future of health care. These priorities were published today in the special publication, *Priorities on the Health Horizon*. To identify these priorities, [...]

National Academy of Sciences - USA [to 13 Nov 2021]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 13 Nov 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 13 Nov 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

No new digest content identified.

PATH [to 13 Nov 2021]

<https://www.path.org/media-center/>

Press Releases

[New panel of antibodies available to support the development of affordable pneumococcal vaccines](#)

New high-quality and affordable serotype-specific monoclonal antibodies (mAbs) now globally available to support vaccine manufacturers in the development of pneumococcal vaccines

Published: 11 November 2021

Press Release

[DRC makes historic gains in child immunization coverage](#)

Child immunization coverage in the Democratic Republic of Congo (DRC) rises to 53 percent—a historic gain announced by the President Felix Tshisekedi at the launch of the second Forum on Vaccination and the Eradication of Polio

Published: 11 November 2021

Announcement

Sabin Vaccine Institute [to 13 Nov 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 13 Nov 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

10 November 2021

Kingston declares World AIDS Day as a commemorative day of public interest

10 November 2021

UNAIDS is deeply saddened by the sudden death of Ly Penh Sun

8 November 2021

Retention in care a growing concern

UNHCR Office of the United Nations High Commissioner for Refugees [to 13 Nov 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

IOM, UNHCR provide emergency aid to asylum-seekers and migrants at the Belarus-Poland border, call to ensure well-being of people and prevent loss of life

12 Nov 2021

UNHCR: World must turn COP26 words into action for forcibly displaced and stateless people

12 Nov 2021

UNHCR: Conflict, violence, climate change drove displacement higher in first half of 2021

11 Nov 2021

Fighting in eastern Democratic Republic of the Congo forces 11,000 to flee to Uganda

9 Nov 2021

UNHCR: Urgent steps needed now to mitigate climate impact on displaced people

7 Nov 2021

UNICEF [to 13 Nov 2021]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

11/11/2021

Global progress against measles threatened amidst COVID-19 pandemic

The largest increase in unvaccinated children in 20 years and critical gaps in disease surveillance increase risk of measles outbreaks, putting lives at risk

[See Milestones/Perspectives above for detail]

Press release

11/09/2021

Nearly 240 million children with disabilities around the world, UNICEF's most comprehensive statistical analysis finds

New report from UNICEF exposes the depth of deprivation experienced by the 1 in 10 children with disabilities worldwide across several indicators of well-being, including health, education and protection.

Statement

11/09/2021

UNICEF deeply concerned about instrumentalization and pushbacks of children on Europe's borders

In 2021, children have been repeatedly caught in the midst of political and border management disputes on the EU's external borders. These developments call for a renewed commitment to the protection, safe-guarding, and best interests of children.

Unitaid [to 13 Nov 2021]

<https://unitaid.org/>

Featured News

12 November 2021

Unitaid marks World Pneumonia Day and calls on all partners for more funding to the oxygen response

11 November 2021

Unitaid launches Climate Action Roadmap as UN Climate Change Conference urges action

09 November 2021

FIND and Unitaid invest US\$ 50 million to speed lifesaving testing and treatment solutions to the COVID-19 pandemic's frontlines

:: New funding to the COVID-19 response across seven complementary grants will help fill testing and treatment gaps
:: The grants, adapting novel strategies to the needs of 22 low- and middle-income countries, will focus on generating robust evidence for global scale-up
:: These grants have been made in the context of the diagnostics and the therapeutics pillars of the Access to COVID-19 Tools (ACT) Accelerator, designed to rapidly address global inequities in access to COVID-19 testing and treatment

Vaccine Equity Cooperative [nee Initiative] [to 13 Nov 2021]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 13 Nov 2021]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 13 Nov 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children’s Hospital of Philadelphia [to 13 Nov 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Feature Article: 3 Considerations for COVID-19 Vaccination of 5- to 11-year-old Children

Published on Nov 11, 2021 in [Parents PACK](#)

Wellcome Trust [to 13 Nov 2021]

<https://wellcome.ac.uk/news>

News and reports

News

Ijeoma Uchegbu appointed to Wellcome's board

9 November 2021

Professor Ijeoma Uchegbu will be joining Wellcome’s Board of Governors, the external experts who oversee all our work and provide support and challenge to our executive team.

Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at University College London (UCL) and the Chief Scientific Officer of Nanomerics. She is also a co-founder of Nanomerics and is a member of the Scientific Advisory Board of the Oxford Centre for Drug Delivery Devices at the University of Oxford.

The Wistar Institute [to 13 Nov 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

Nov. 11, 2021

Wistar Scientists Discover Sugar Molecule on HIV-infected Cell Plays Role in Evading Immune System — They Exploit as Weakness to Make More Effective “Natural Killers” Against HIV

A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, shows how key features on the surface of HIV-infected cells help the disease evade detection by the immune system. It also shows how these features can be disabled. The findings, published in PLOS Pathogens, are a first step toward a new class of treatment aimed at not just suppressing virus replication, but killing cells harboring persistent virus that prevent us from curing HIV infection.

WFPHA: World Federation of Public Health Associations [to 13 Nov 2021]

<https://www.wfpha.org/>

Latest News

No new digest content identified.

World Bank [to 13 Nov 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Second phase of phone surveys to monitor the impacts of COVID-19 in Latin American and Caribbean countries

Latin American and the Caribbean (LAC) has been one of the regions in the world most affected by the COVID-19 pandemic. Between March and August 2020, the World Bank conducted a series of High-Frequency...

Date: November 12, 2021 Type: Statement

Tales of Hope and Resilience: Support to Displaced Rohingya and Local Communities in Cox's Bazar, Bangladesh

Since 2017, Bangladesh has provided shelter to more than a million Rohingya people who have fled violence in Myanmar. The influx has placed enormous pressure on local infrastructure and stretched service...

Date: November 11, 2021 Type: Brief

International organizations, vaccine manufacturers take stock of COVID-19 vaccine rollout, share views for 2022

Joint Statement of the Multilateral Leaders Task Force on Scaling COVID-19 Tools The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization held on...

Date: November 09, 2021 Type: Statement

[See Milestones/Perspectives above for detail]

Future of Food: Building Stronger Food Systems in Fragility, Conflict, and Violence Settings

Achieving the UN Sustainable Development Goals is impossible without addressing fragility, conflict, and violence (FCV), especially as two thirds of the extreme poor are projected to live in such...

Date: November 08, 2021 Type: Publication

World Organisation for Animal Health (OIE) [to 13 Nov 2021]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 13 Nov 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

DDG Zhang stresses role of trade in advancing development and facilitating peace

10 November 2021

The WTO accession process can help to address the technology gap between least-developed countries (LDCs) and fragile and conflict-affected states (FCSs) and more developed economies, said Deputy Director-General Zhang. Speaking at a session of the World Summit on Information Society (WSIS) Forum on 10 November, DDG Zhang explained that trade-related aspects of e-commerce and technology transfer can support the peace agenda and the WTO's Trade for Peace Programme. His remarks are below.

International organizations, vaccine manufacturers take stock of COVID-19 vaccine roll out, share views for 2022

9 November 2021

The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization held on 9 November the 2nd High-Level Consultations with the CEOs of leading COVID-19 vaccine manufacturing companies. At the meeting, all participants agreed on the urgency of delivering more vaccine doses to low-income countries, where less than 2.5% of the population has been fully vaccinated.

[See Milestones/Perspectives above for detail]

WTO launches improved quantitative restrictions database

8 November 2021

The WTO launched on 8 November an improved Quantitative Restrictions (QR) Database, an online platform to search and retrieve information on trade restrictions and prohibitions notified by WTO members. The QR Database provides information on export prohibitions and restrictions introduced by members in response to the COVID-19 pandemic, with detailed information on the affected products, the intended duration of the measures and their WTO justification.

::::::

ARM [Alliance for Regenerative Medicine] [to 13 Nov 2021]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 13 Nov 2021]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 13 Nov 2021]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 13 Nov 2021]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 13 Nov 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 13 Nov 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 13 Nov 2021]

<http://www.phrma.org/>

Latest News [Selected]

PhRMA Statement on the Nomination of Dr. Robert Califf to Lead the U.S. Food and Drug Administration

Nov 12, 2021

“Congratulations to Dr. Robert Califf for being nominated as the next commissioner of the U.S. Food and Drug Administration...

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 11: E833-904

<https://journalofethics.ama-assn.org/issue/health-care-and-homelessness>

Health Care and Homelessness

Homelessness dramatically undermines personal and community health status. Throughout their lifespans, children, elders, and all who are chronically unsheltered confront cumulative health detriments of exposure, violence, and poor nutrition. With limited access to hygiene opportunities and health services, people experiencing homelessness endure poor continuity of care and some of the poorest health outcomes tolerated in the US health care system.

[Reviewed earlier]

American Journal of Infection Control

November 2021 Volume 49 Issue 11 p1343-1456

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

November 2021 Volume 61 Issue 5 p619-770

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

October 2021 111(10)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 2 (Aug 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

October 2021 Volume 174, Issue 10

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 300 November 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/300/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 13 Nov 2021)

[No new digest content identified]

BMJ Global Health

November 2021 - Volume 6 - 11

<https://gh.bmjjournals.org/content/6/11>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 13 Nov 2021)

Utilization of health care services before and after media attention about fatal side effects of the AstraZeneca vaccine: a nation-wide register-based event study

Survey studies have found that vaccinated persons tend to report more side effects after being given information about side effects rather than benefits. However, the impact of high media attention about vacci...

Authors: Vilde Bergstad Larsen, Mari Grøsland, Kjetil Telle and Karin Magnusson

Citation: BMC Health Services Research 2021 21:1229

Content type: Research

Published on: 13 November 2021

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 13 Nov 2021)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 13 Nov 2021)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 13 Nov 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 13 Nov 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 13 Nov 2021)

Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here

Strategies to control coronavirus 2019 disease (COVID-19) have often been based on preliminary and limited data and have tended to be slow to evolve as new evidence emerges. Yet knowledge about COVID-19 has gr...

Authors: Daniel T. Halperin, Norman Hearst, Stephen Hodgins, Robert C. Bailey, Jeffrey D. Klausner, Helen Jackson, Richard G. Wamai, Joseph A. Ladapo, Mead Over, Stefan Baral, Kevin Escandón and Monica Gandhi

Citation: BMC Public Health 2021 21:2084

Content type: Review

Published on: 13 November 2021

Age-appropriate vaccination coverage and its determinants in children aged 12–36 months in Nepal: a national and subnational assessment

Vaccination is one of the effective ways to develop immunity against potential life-threatening diseases in children in early age. This study is focused on analysing the age-appropriate vaccination coverage at...

Authors: Santosh Kumar Rauniyar, Yoko Iwaki, Daisuke Yoneoka, Masahiro Hashizume and Shuhei Nomura

Citation: BMC Public Health 2021 21:2063

Content type: Research

Published on: 10 November 2021

HPV vaccine: uptake and understanding among global Indigenous communities – a qualitative systematic review

Indigenous populations have a high prevalence of Human Papillomavirus (HPV) infection and a high incidence of HPV associated cancers, such as cervical and oropharyngeal cancer. There is an effective HPV vaccin...

Authors: Brianna Poirier, Sneha Sethi, Gail Garvey, Joanne Hedges, Karen Canfell, Megan Smith, Xiangqun Ju and Lisa Jamieson

Citation: BMC Public Health 2021 21:2062

Content type: Research

Published on: 10 November 2021

How can the public health impact of vaccination be estimated?

Deaths due to vaccine preventable diseases cause a notable proportion of mortality worldwide. To quantify the importance of vaccination, it is necessary to estimate the burden averted through vaccination. The ...

Authors: Susy Echeverria-Londono, Xiang Li, Jaspreet Toor, Margaret J. de Villiers, Shevanthi Nayagam, Timothy B. Hallett, Kaja Abbas, Mark Jit, Petra Klepac, Kévin Jean, Tini Garske, Neil M. Ferguson and Katy A. M. Gaythorpe

Citation: BMC Public Health 2021 21:2049

Content type: Research

Published on: 9 November 2021

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 13 Nov 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2021 - Volume 26 - 5

<https://ebm.bmj.com/content/26/5>

[Reviewed earlier]

BMJ Open

November 2021 - Volume 11 - 11

<https://bmjopen.bmj.com/content/11/11>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(11); 2021 Nov 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/392423/>

[Reviewed earlier]

Cell

Nov 11, 2021 Volume 184 Issue 23 p5691-5838

<https://www.cell.com/cell/current>

Articles

[Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine](#)

Rebecca P. Payne, et al. on behalf of the PITCH Consortium

Open Access

After giving a primary dose, delaying administration of a second dose of BNT162b2 COVID-19 vaccine up to 6–14 weeks continues to provide strong protection and contributes to favorable antibody, B cell, and T cell responses.

Child Care, Health and Development

Volume 47, Issue 6 Pages: 733-885 November 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 5 Pages: 1137-1402 November 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

September 2021 Volume 43 Issue 9 p1435-1626
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 18 Issue 6, December 2021
<https://journals.sagepub.com/toc/ctja/18/6>

Articles

Characteristics of available studies and dissemination of research using major clinical data sharing platforms

Enrique Vazquez, Henri Gouraud, Florian Naudet, Cary P Gross, Harlan M Krumholz, Joseph S Ross, Joshua D Wallach

First Published August 18, 2021; pp. 657–666

Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data

Conner L Jackson, Kathryn Colborn, Dexiang Gao, Sangeeta Rao, Hannah C Slater, Sunil Parikh, Brian D Foy, John Kittelson

First Published July 3, 2021; pp. 582–593

Ethics

Navigating the ethics of remote research data collection

Luke Gelinas, Walker Morrell, Sarah A White, Barbara E Bierer

First Published July 7, 2021; pp. 606–614

Design

Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom

M Estée Török, Benjamin R Underwood, Mark Toshner, Claire Waddington, Emad Sidhom, Katherine Sharrocks, Rachel Bousfield, Charlotte Summers, Caroline Saunders, Zoe McIntyre, Helen Morris, Jo Piper, Gloria Calderon, Sarah Dennis, Tracy Assari, Anita Marguerie de Rotrou, Ashley Shaw, John Bradley, John O'Brien, Robert C Rintoul, Ian Smith, Ed Bullmore, Krishna Chatterjeeon behalf of the Cambridge COVID Vaccine Trial Team

First Published June 22, 2021; pp. 615–621

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 13 Nov 2021]

[No new digest content identified]

Contemporary Clinical Trials

Volume 110 November 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/110/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 4, Issue 5 / October 2021

<https://www.liebertpub.com/toc/crispr/4/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2021 - Volume 34 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

TROPICAL AND TRAVEL-ASSOCIATED DISEASES

Edited by Christina M. Coyle

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 3 Pages: 97-148 September 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 7, 2021

<http://www.tandfonline.com/toc/cdip20/current>

The Private Sector in the Development Landscape.

Guest Editors: Jason Hart, Jo-Anna Russon & Jessica Sklair

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 45, Issue 4 Pages: 739-995 October 2021
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 22 Issue 11 4 November 2021
<https://www.embopress.org/toc/14693178/current>
Science & Society 20 October 2021 *Open Access*

[AI revolutions in biology: The joys and perils of AlphaFold](#)

Anastassis Perrakis, Titia K Sixma

AlphaFold is the most ground-breaking application of AI in science so far; it will revolutionize structural biology, but caution is warranted.

Science & Society 4 November 2021 *Open Access*

[Involving society in science: Reflections on meaningful and impactful stakeholder engagement in fundamental research](#)

Helen Garrison et al

Open Science calls for transparent science and involvement of various stakeholders. Here are examples of and advice for meaningful stakeholder engagement.

Emerging Infectious Diseases

Volume 27, Number 11—November 2021
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 36 September 2021
<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 5 Pages: 1-44 September–October 2021
<https://onlinelibrary.wiley.com/toc/25782363/current>
[Reviewed earlier]

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

September 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue 5, October 2021

<https://academic.oup.com/eurpub/issue/31/5>

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (10) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 13 Nov 2021]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 3 September 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 13 Nov 2021]

[No new digest content identified]

Global Public Health

Volume 16, Issue 12 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 13 Nov 2021]

[No new digest content identified]

Health and Human Rights

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 9, November 2021

<https://academic.oup.com/heapol/issue/36/9>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 13 Nov 2021]

[No new digest content identified]

Human Gene Therapy

Volume 32, Issue 19-20 / October 2021
<https://www.liebertpub.com/toc/hum/32/19-20>
[Reviewed earlier]

Humanitarian Exchange Magazine

Number 79, May 2021
<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>
Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021
<https://www.tandfonline.com/toc/khvi20/current>
[Reviewed earlier]

Immunity [NEW JOURNAL ADDED]

Nov 09, 2021 Volume 54 Issue 11 p2437-2670
<https://www.cell.com/immunity/current>
[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>
[Accessed 13 Nov 2021]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjurnal.com/content>

[Accessed 13 Nov 2021]
[No new digest content identified]

International Health

Volume 13, Issue 5, September 2021
<https://academic.oup.com/inthealth/issue/13/5>
[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)
<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 10 (2021) October 2021
<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>
[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 5, October 2021
<https://academic.oup.com/ije/issue>
[New issue; No digest content identified]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases

October 2021 Volume 111 p1-362
<https://www.ijidonline.com/current>
[Reviewed earlier]

JAMA

November 9, 2021, Vol 326, No. 18, Pages 1771-1880
<https://jamanetwork.com/journals/jama/currentissue>
Original Investigation
Caring for the Critically Ill Patient

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe HypoxemiaThe COVID STEROID 2 Randomized Trial

The COVID STEROID 2 Trial Group

Research Letter

COVID-19 Incidence and Mortality in Federal and State Prisons Compared With the US Population, April 5, 2020, to April 3, 2021

Neal Marquez, MPH; Julie A. Ward, MN, RN; Kalind Parish, MA; et al.
free access

JAMA. 2021;326(18):1865-1867. doi:10.1001/jama.2021.17575

This study examines COVID-19 cases and deaths among US federal and state prisoners from April 5, 2020, to April 3, 2021, compared with cases and deaths in the overall US population.

Viewpoint

A Policy Prescription for Reducing Health Disparities—Achieving Pharmacoequity

Utibe R. Essien, MD, MPH; Stacie B. Dusetzina, PhD; Walid F. Gellad, MD, MPH
free access has audio

JAMA. 2021;326(18):1793-1794. doi:10.1001/jama.2021.17764

This Viewpoint discusses pharmacoequity, which is the goal of ensuring that all individuals have access to the highest-quality medications required to manage their health needs, and ways in which this can be achieved.

[Audio Author Interview: A Continued Focus on Equity Through Pharmacoequity and Digital Health Equity: Two Current Viewpoints](#)

Focusing on Digital Health Equity

Courtney R. Lyles, PhD; Robert M. Wachter, MD; Urmimala Sarkar, MD, MPH
free access has audio

JAMA. 2021;326(18):1795-1796. doi:10.1001/jama.2021.18459

This Viewpoint describes ways in which health care digital tools and platforms can be designed and implemented to address long-standing health equity disparities.

JAMA Network

COVID-19 Update November 13, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

November 2021, Vol 175, No. 11, Pages 1093-1192
<https://jamanetwork.com/journals/jamapediatrics/currentissue>
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>
[Reviewed earlier]

JBI Evidence Synthesis

October 2021 - Volume 19 - Issue 10
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

November 2021 Volume 69 Issue 5

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 5, October 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-5>

[Reviewed earlier]

Journal of Development Economics

Volume 153 November 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/153/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 5, December 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

October 2021 - Volume 75 - 10

<https://jech.bmjjournals.org/content/75/10>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 1, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

Journal of Medical Ethics

November 2021 - Volume 47 - 11

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 4 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

Cancer Screening

[Reviewed earlier]

Journal of Pediatrics

November 2021 Volume 238 p1-348

<http://www.jpeds.com/current>

Special Communication

[Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents](#)

Sarah S. Long

Published online: July 29, 2021

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 13 Nov 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

November/December 2021 - Volume 27 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 3, September 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-3>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

November 2021 Volume 18 Issue 184

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 7, October 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 95 • Number 21 • October 2021

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Nov 13, 2021 Volume 398 Number 10313 p1777-1850

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

100 years of insulin: a technical success but an access failure

The Lancet

Articles

Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study

Raphael Sonabend, et al.

Open Access

Findings

The roadmap policy was successful in offsetting the increased transmission resulting from lifting NPIs starting on March 8, 2021, with increasing population immunity through vaccination. However, because of the emergence of the delta variant, with an estimated transmission advantage of 76% (95% credible interval [95% CrI] 69–83) over alpha, fully lifting NPIs on June 21, 2021, as originally planned might have led to 3900 (95% CrI 1500–5700) peak daily hospital admissions under our central parameter scenario. Delaying until July 19, 2021, reduced peak hospital admissions by three fold to 1400 (95% CrI 700–1700) per day. There was substantial uncertainty in the epidemic trajectory, with particular sensitivity to the transmissibility of delta, level of mixing, and estimates of vaccine effectiveness.

Interpretation

Our findings show that the risk of a large wave of COVID-19 hospital admissions resulting from lifting NPIs can be substantially mitigated if the timing of NPI relaxation is carefully balanced against vaccination coverage. However, with the delta variant, it might not be possible to fully lift NPIs without a third wave of hospital admissions and deaths, even if vaccination coverage is high. Variants of concern, their transmissibility, vaccine uptake, and vaccine effectiveness must be carefully monitored as countries relax pandemic control measures.

The Lancet Child & Adolescent Health

Nov 2021 Volume 5 Number 11 p767-836

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Nov 2021 Volume 3 Number 11 e684-e750

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Nov 2021 Volume 9 Number 11 e1474-e1622

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Nov 2021 Volume 21 Number 11 p1471-1612, e341-e362

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Nov 2021 Volume 6 Number 11 e780-e865

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Nov 2021 Volume 9 Number 11 p1203-1342, e104-e109

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 11, November 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-11>

Original Paper

[COVID-19 and Children's Well-Being: A Rapid Research Agenda](#)

Authors (first, second and last of 8) Rebecca N. Dudovitz, Shirley Russ, Neal Halfon

Open Access

Published: 24 August 2021

Pages: 1655 - 1669

[The Relationship Between Household Microfinance Group Participation and Vaccine Adherence Among Children in Rural Western Kenya](#)

Authors (first, second and last of 12) Jessica E. Deyoe, James Akiruga Amisi, Molly Rosenberg

Content type: Original Paper

Published: 18 August 2021

Pages: 1725 - 1734

Medical Decision Making (MDM)

Volume 41 Issue 8, November 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 3 Pages: 601-852 September 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 599 Issue 7884, 11 November 2021

<https://www.nature.com/nature/volumes/599/issues/7884>

Editorial | 10 November 2021

[COVID is disrupting scientific careers around the world](#)

Earlier generations faced fallout from the global financial crisis and a boost from emerging economies. Today, COVID-19 and concerns about diversity dominate.

Nature Biotechnology

Volume 39 Issue 11, November 2021

<https://www.nature.com/nbt/volumes/39/issues/11>

Editorial | 27 October 2021

[How biomanufacturing can save the world](#)

With supply-chain shortages and production problems exacerbating vaccine inequity, global manufacturing must expand to ensure the world's poorest nations are better served.

News | 09 November 2021

[Sickle cell gene therapies approach watershed](#)

Early results promise a one-off treatment, but gene-editing and gene therapies will have to show durable protection and be affordable to the many patients with sickle cell disease in the world.

Cormac Sheridan

Patents | 09 November 2021

[Drug delivery](#)

Recent patents relating to methods of delivering RNA, protein and antibody therapeutics.

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 13 Nov 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 11, November 2021

<https://www.nature.com/ng/volumes/53/issues/11>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 10, October 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/10>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 10, October 2021

<https://www.nature.com/nm/volumes/27/issues/10>

[Reviewed earlier]

Nature Reviews Genetics

Volume 22 Issue 11, November 2021

<https://www.nature.com/nrg/volumes/22/issues/11>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 11, November 2021

<https://www.nature.com/nri/volumes/21/issues/11>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 11, November 2021

<https://www.nature.com/nrd/volumes/20/issues/11>

[Reviewed earlier]

New England Journal of Medicine

November 11, 2021 Vol. 385 No. 20

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[The Future of SARS-CoV-2 Vaccination — Lessons from Influenza](#)

A.S. Monto

EDitorials

[Audio Interview: Covid-19 in Brazil and New Evidence for Vaccinating Younger Children](#)

E.J. Rubin, L.R. Baden, B. Grinsztejn, and S. Morrissey

Pediatrics

Vol. 148, Issue 5 1 Nov 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 11, November 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-11>

Current Opinion

[Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic](#)

Authors (first, second and last of 6) Yumi Asukai, Andrew Briggs, Daniel A. Ollendorf

Open Access

Published: 24 September 2021

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 13 Nov 2021)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 13 Nov 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 13 Nov 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 13 Nov 2021)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 13 Nov 2021]

Research Article

[COVID-19 vaccine hesitancy and refusal and associated factors in an adult population in Saskatchewan, Canada: Evidence from predictive modelling](#)

Nazeem Muhajarine, Daniel A. Adeyinka, Jessica McCutcheon, Kathryn L. Green, Miles Fahlman, Natalie Kallio

Research Article | published 12 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0259513>

[A social norms approach intervention to address misperceptions of anti-vaccine conspiracy beliefs amongst UK parents](#)

Darel Cookson, Daniel Jolley, Robert C. Dempsey, Rachel Povey

Research Article | published 12 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258985>

[Using moral foundations in government communication to reduce vaccine hesitancy](#)

Florian Heine, Ennie Wolters

Research Article | published 09 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0259435>

[Reasons for nonadherence to vaccination for influenza among older people in Brazil](#)

Aldiane Gomes de Macedo Bacurau, Ana Paula Sayuri Sato, Priscila Maria Stolzes Bergamo Francisco
Research Article | published 08 Nov 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0259640>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 13 Nov 2021]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

November 02, 2021; vol. 118 no. 44
<https://www.pnas.org/content/118/44>
[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 5 - October 2021
<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 152, Part 1, November 2021
<https://www.sciencedirect.com/journal/preventive-medicine/vol/152/part/P1>
[New issue; No digest content identified]

Proceedings of the Royal Society B

10 November 2021 Volume 288 Issue 1962
<https://royalsocietypublishing.org/toc/rspb/current>
[Reviewed earlier]

Public Health

Volume 200 Pages e1-e10, 1-124 (November 2021)
<https://www.sciencedirect.com/journal/public-health/vol/200/suppl/C>

Short communication Full text access

[**An analysis of AstraZeneca COVID-19 vaccine misinformation and fear mongering on Twitter**](#)

D. Jemielniak, Y. Krempovych
Pages 4-6

Short communication Full text access

[**Vaccine hesitancy among working-age adults with/without disability in the UK**](#)

E. Emerson, V. Totsika, Z. Aitken, T. King, ... A. Kavanagh
Pages 106-108

Public Health Ethics

Volume 14, Issue 2, July 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 6, November/December 2021

<https://journals.sagepub.com/toc/phrg/136/6>

Research

[Racial/Ethnic Disparities in Maternal Vaccine Knowledge, Attitudes, and Intentions](#)

Matthew Z. Dudley, PhD, Rupali J. Limaye, PhD, Daniel A. Salmon, PhD, Saad B. Omer, MBBS, Sean T. O'Leary, MD, Mallory K. Ellingson, MPH, Christine I. Spina, MSPH, Sarah E. Brewer, PhD, Robert A. Bednarczyk, PhD, Fauzia Malik, PhD, Paula M. Frew, PhD, Allison T. Chamberlain, PhD

First Published January 28, 2021; pp. 699–709

[Acceptance of COVID-19 Vaccine Among Refugees in the United States](#)

Mengxi Zhang, PhD, MPH, Ashok Gurung, MS, Philip Anglewicz, PhD, Parangkush Subedi, MPH, Colleen Payton, PhD, MPH, Ahmed Ali, PharmD, Anisa Ibrahim, MD, Mahri Haider, MD, MPH, Navid Hamidi, BS, Jacob Atem, PhD, MPH, Jenni Thang, BA, Siqin Wang, PhD, Curi Kim, MD, MPH, Sarah L. Kimball, MD, Fatima Karaki, MD, Najib Nazhat, BA, Mouammar Abouagila, BA, Katherine Yun, MD, MHS

First Published September 21, 2021; pp. 774–781

Qualitative Health Research

Volume 31 Issue 13, November 2021

<https://journals.sagepub.com/toc/qhra/current>

[New issue; No digest content identified]

Research Ethics

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 13 Nov 2021]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 41, Issue 9 Pages: 1497-1735 September 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 13 Nov 2021]

[Reviewed earlier]

Science

Volume 374| Issue 6569| 12 Nov 2021

<https://www.science.org/toc/science/current>

Reports

[Monetary incentives increase COVID-19 vaccinations](#)

BY Pol Campos-Mercade, Armando N. Meier, Florian H. Schneider, Stephan Meier, Devin Pope, Erik Wengström

07 Oct 2021: 879-882

Open Access

In Sweden, monetary incentives of US \$24 increased vaccination rates from approximately 72% to approximately 76%.

Science Translational Medicine

Volume 13| Issue 619| 10 Nov 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 287 October 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/287/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 13 Nov 2021]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>
[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 43 September–October 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/43/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 11 Pages: i-iv, 1325-1525 November 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>
[Reviewed earlier]

Vaccine

Volume 39, Issue 45 Pages 6565-6712 (29 October 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/45>

Discussion No access

[All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions](#)

Yihua Bruce Yu, Marc B. Taraban, Katharine T. Briggs

Pages 6565-6569

Discussion Full text access

[The influenza vaccines roadmap – A better future through improved influenza vaccines](#)

Peter Hart, Jeremy Farrar

Pages 6570-6572

Review article Open access

[A Research and Development \(R&D\) roadmap for influenza vaccines: Looking toward the future](#)

Kristine A. Moore, Julia T. Ostrowsky, Alison M. Kraigsley, Angela J. Mehr, ... Jerry Weir

Pages 6573-6584

Short communication Full text access

[Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity](#)

Kimberly A. Fisher, Ngoc Nguyen, Sybil Crawford, Hassan Fouayzi, ... Kathleen M. Mazor

Pages 6591-6594

Short communication Open access

[Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform](#)

Liudmila Mosina, Wiebe Külper-Schiek, Lisa Jacques-Carroll, Andrew Earnshaw, ... Siddhartha Sankar Datta

Pages 6595-6600

Research article Full text access

Christian nationalism and COVID-19 vaccine hesitancy and uptake

Katie E. Corcoran, Christopher P. Scheitle, Bernard D. DiGregorio

Pages 6614-6621

Research article Abstract only

Vaccination coverage among young homeless children compared to US national immunization survey data

Linda Y. Fu, Rachel Torres, Susan Caleb, Yao I. Cheng, ... Jichuan Wang

Pages 6637-6643

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 13 Nov 2021]

Research article Abstract only

Vaccination coverage among young homeless children compared to US national immunization survey data

Linda Y. Fu, Rachel Torres, Susan Caleb, Yao I. Cheng, ... Jichuan Wang

Pages 6637-6643

Open Access Feature Paper Article

Anti-COVID Vaccination for Adolescents: A Survey on Determinants of Vaccine Parental Hesitancy

by Stefano Zona et al.

Vaccines 2021, 9(11), 1309; <https://doi.org/10.3390/vaccines9111309> - 10 Nov 2021

Abstract

Vaccine hesitancy has been considered one of the most severe threats to global health, as it represents an obstacle to achieving adequate vaccination coverage. Recent research studies aimed at investigating the propensity for anti-COVID vaccination among adults have found a high prevalence of [...]

Open Access Article

Prevalence and Factors Associated with Parents' Non-Intention to Vaccinate Their Children and Adolescents against COVID-19 in Latin America and the Caribbean

by Diego Urrunaga-Pastor, et a.

Vaccines 2021, 9(11), 1303; <https://doi.org/10.3390/vaccines9111303> - 09 Nov 2021

Abstract

We aimed to estimate the prevalence and factors associated with parents' non-intention to vaccinate their children and adolescents against COVID-19 in Latin America and the Caribbean (LAC). We performed a secondary analysis using a database generated by the University of Maryland and Facebook [...]

Value in Health

November 2021 Volume 24 Issue 11 p1543-1714

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

:::::::
:::::::

Pre-Print Servers

bioRxiv

<https://www.biorxiv.org/>

bioRxiv (pronounced "bio-archive") is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.

[Accessed 13 Nov 2021]

Potent antibody immunity to SARS-CoV-2 variants elicited by a third dose of inactivated vaccine

Bin Ju, Bing Zhou, Shuo Song, Qing Fan, Xiangyang Ge, Haiyan Wang, Lin Cheng, Huimin Guo, Dan Shu, Lei Liu, Zheng Zhang

bioRxiv 2021.11.10.468037; doi: <https://doi.org/10.1101/2021.11.10.468037>

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern

Marzi, A., Griffin, A., O'Donnell, K. L., Shifflett, K., Lavik, J.-P., Russell, P. M., Zimmerman, M. K., Relich, R. F.

[10.1101/2021.11.10.468174](https://doi.org/10.1101/2021.11.10.468174) — Posted: 2021-11-12

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 13 Nov 2021]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[Accessed 13 Nov 2021]

Selected Content

Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Tang, P. J., Hasan, M. R., Coyle, P., YASSINE, H. M., Benslimane, F., Al-Khatib, H. A., Al-Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif,

A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G., Al Kuwari, M. G., Butt, A. A., Al Romaihi, H. E., Al-Thani, M. H., Al Khal, A., Bertollini, R.

10.1101/2021.11.12.21266250 — Posted: 2021-11-13

[Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January to September 2021.](#)

Starrfelt, J., Buanes, E. A., Juvet, L. K., Lyngstad, T. M., Ro, G. O. I., Veneti, L., Meijerink, H.

10.1101/2021.11.12.21266222 — Posted: 2021-11-12

[Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence.](#)

Rosero-Bixby, L.

10.1101/2021.11.08.21266087 — Posted: 2021-11-09

[Parents intention to vaccinate their 5-11 years old children with the COVID-19: vaccine rates, predictors and the role of incentives](#)

Shmueli, L.

10.1101/2021.11.05.21265900 — Posted: 2021-11-09

[Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections](#)

hoque, a., Rahman, M., Imam, H., Nahar, N., Hasan Chowdhury, F. U.

10.1101/2021.11.08.21266037 — Posted: 2021-11-09

[Surveillance of COVID-19 in a Vaccinated Population: A Rapid Literature Review](#)

Egunsola, O., Farkas, B., Flanagan, J., Salmon, C., Mastikhina, L., Clement, F.

10.1101/2021.11.05.21265763 — Posted: 2021-11-08

[A need of COVID19 vaccination for children aged <12 years: Comparative evidence from the clinical characteristics in patients during a recent Delta surge \(B.1.617.2\)](#)

Li, H., Lin, H., Chen, X., Li, H., Li, H., Lin, S., Huang, L., Chen, G., Zheng, G., Wang, S., Hu, X., Huang, H., Tu, H., Li, X., Ji, Y., Zhong, W., Li, Q., Fang, J., Lin, Q., Yu, R., Xie, B.

10.1101/2021.11.05.21265712 — Posted: 2021-11-08

[Defining the determinants of under-vaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review](#)

Crawshaw, A. F., Farah, Y., Deal, A., Rustage, K., Hayward, S. E., Carter, J., Knights, F., Goldsmith, L. P., Campos-Matos, I., Wurie, F., Majeed, A., Bedford, H., Forster, A. S., Hargreaves, S.

10.1101/2021.11.08.21266058 — Posted: 2021-11-08

Wellcome Open Research [to 13 Nov 2021]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 13 Nov 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Systematic Review metrics AWAITING PEER REVIEW

[The hidden financial burden of healthcare: a systematic literature review of informal payments in Sub-Saharan Africa](#) [version 1; peer review: awaiting peer review]

Evelyn Kibia, Catherine Goodman, Dina Balabanova, Kui Muraya, Sassy Molyneux, Edwine Barasa
Peer Reviewers Invited

Funder: Wellcome

PUBLISHED 08 Nov 2021

* * *

Think Tanks

Brookings [to 13 Nov 2021]

<http://www.brookings.edu/>

Accessed 13 Nov 2021

[No new digest content identified]

Center for Global Development [to 13 Nov 2021]

<http://www.cgdev.org/page/press-center>

Accessed 13 Nov 2021

[Why I'm Embarrassed to Receive a COVID Booster](#)

November 12, 2021

Obviously, an ethical vaccine distribution would start with a far more equitable sharing of vaccines between rich and less-rich nations. More pragmatically, the current huge imbalance in the global distribution of shots invites another outbreak of a new variant, against which the US and other high-income countries cannot insulate themselves.

[Nancy Birdsall](#)

[Staffing Shortages in the UK's Care Sector: A Sign of Things to Come](#)

November 11, 2021

Today the UK government's new policy of mandatory vaccination for care home workers takes effect. By the government's own reckoning this could result in up to 12 percent of workers in residential care settings leaving their jobs. How worried should we be about staff shortages in the care sector? In short, very.

[Claire Kumar](#) and [Helen Dempster](#)

[Financing our Global Health Commons](#)

Event

11/10/21

COVID-19 will likely be a forerunner of future catastrophic pandemics, fueled by global warming and biodiversity losses, unless significant new investments and reforms are urgently made to bolster capacities and resilient adaptive systems for pandemic preparedness and rapid response. This session will present the conclusions and recommendations of the G20 High Level Independent panel on

financing the global commons for pandemic preparedness and control, highlighting the interconnectedness of the pandemic preparedness and the climate change agenda

Chatham House [to 13 Nov 2021]

<https://www.chathamhouse.org/>

Accessed 13 Nov 2021

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 13 Nov 2021

Upcoming Event

[COVAX Past, Present, and Future: A Conversation with Dr. Seth Berkley](#)

November 15, 2021

Report

[Adapting Covid-19 Innovations to Accelerate Progress toward Meeting Global Tuberculosis Goals](#)

November 12, 2021 | By [Katherine E. Bliss](#)

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 13 Nov 2021

November 8, 2021 *News Release*

[COVID-19 Misinformation is Ubiquitous: 78% of the Public Believes or is Unsure About At Least One False Statement, and Nearly a Third Believe At Least Four of Eight False Statements Tested](#)

Most People Who Trust Network and Local Television, CNN, MSNBC and NPR on COVID-19 Believe Little or No Misinformation; Larger Shares Who Trust Newsmax, One American News, and Fox News Hold Many Misconceptions More than three quarters (78%) of U.S. adults either believe or aren't sure about at least one...

ODI [Overseas Development Institute] [to 13 Nov 2021]

<https://odi.org/en/publications/>

Publications

[No new digest content identified]

*

*

*

*

*

*

*

*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *